Galderma Laboratories, headquartered in Fort Worth, Texas, will be gaining rights to several dermatological products through an agreement between Nestlé S.A. and Valeant Pharmaceuticals International, Inc. Galderma will be adding Restylane, Perlane, Emervel, Sculptra, and Dysport to its lineup of skincare items.
“We are very grateful that Nestlé has continued to support Galderma through this transaction,” said Humberto C. Antunes, President and CEO of Galderma worldwide.
Restylane and Perlane, products used to correct moderate to severe facial wrinkles, are already manufactured by Galderma, but Valeant holds the distribution rights for these products in the United States and Canada. Now, Galderma will be able to further develop these products and expand its distribution globally, as its subsidiaries already market the products overseas.
Emervel, which consists of five next generation hyaluronic acid soft dermal fillers to correct facial lines, is similarly manufactured by Galderma. It was originally launched in Europe in 2010, and two products, Emervel Classic and Emervel Deep, are in review by the FDA for approval in the United States.
“This further marks the commitment of Galderma employees in the United States and Canada to aesthetic and corrective dermatology,” said Stuart Raetzman, CEO of Galderma Laboratories, LP and Galderma North America. “We all work together to maintain the industry’s highest standards of clinical safety and efficacy, to bring a wide range of scientifically advanced and clinically proven medical solutions to physicians. Our portfolio of products, combined with exclusive services and medical training programs, positions Galderma as the preferred partner of dermatologists, plastic surgeons and aesthetic physicians.”
Sculptra, a formulation of poly-L-lactic acid, is approved in the United States to treat facial lipoatrophy from human immunodeficiency virus and has cosmetic indications in immune-competent patients. Sculprta Aesthetic is an injection to replace lost collagen and allows Medical Aesthtic clinicians to work directly with patients. Sculptra was owned solely by Valeant, and now Galderma will be able to commercialize in the United States, Canada, and select worldwide locations.
Finally, Dysport (botulinum toxin A), an injection to temporarily improve moderate to severe frown lines between the eyebrows, is already marketed by Galderma in worldwide markets. But again, Valeant holds distribution rights for Dysport’s aesthetic dermatology indications, so the agreement will enable Galderma to commercialize in the United States and Canada. It known as Azzalure in Europe, where it was first approved outside the United States in 1991.
“The United States and Canada represent more than 50 percent of the fast growing global medical aesthetics market,” said Antunes, indicating the importance of the agreement. “This move secures Galderma’s continued ability to invest in product innovation, medical education, customer service, and consumer awareness. Thanks to this agreement with Valeant, Galderma will be able to provide this best-in-class portfolio of fillers and muscle relaxant for aesthetic and corrective dermatology also in the United States and Canada.”
Galderma has over 30 years of history in dermatology, but in February 2014, Nestlé announced the acquisition of 50% of Galderma to form Nestlé Skin Health S.A. Galderma was originally established as a joint-venture between Nestlé and L’Oréal S.A. The new transaction with Valeant is expected to make regulatory clearance by July.